Literature DB >> 11150026

Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.

A Casonato1, E Pontara, F Sartorello, A Bertomoro, C Durante, A Girolami.   

Abstract

We describe a von Willebrand disease (VWD) variant characterized by low plasma and platelet von Willebrand factor (VWF), impaired ristocetin-induced VWF binding to platelet glycoprotein Ib (GPIb), and abnormal VWF multimer pattern not associated with the absence of large forms. A C-to-T transition at nucleotide 4120 in exon 28 of the VWF gene was found; this mutation introduces a cysteine at the codon for Arg 611 of mature VWF. In addition to the decreased factor VIII (FVIII) and VWF levels, ristocetin-induced platelet aggregation (RIPA) was almost absent, and VWF ristocetin cofactor activity (VWF:RCo) was significantly more decreased than VWF antigen. The patients (mother and son) also showed a defect in VWF collagen-binding activity. Plasma VWF multimers were decreased, with no limit in the size of large forms, and the normal discontinuous multimer organization was replaced by a diffuse smear, especially detectable in the large forms. This picture was emphasized by 1-deamino-8-D -arginine vasopressin (DDAVP) infusion, so that the abnormal VWF multimers appeared to have a molecular weight higher than those present in, or released by, human umbilical vein endothelial cells. DDAVP also increased FVIII and VWF levels but did not normalize the GPIb-dependent VWF functions expressed as RIPA and VWF:RCo. We include this variant in type 2M VWD, focusing on the abnormality in GPIb-dependent VWF function. We advance that this defect depends on the mutation in the GPIb binding domain of VWF rather than the abnormal VWF multimer pattern.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150026     DOI: 10.1067/mlc.2001.111252

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  4 in total

1.  Variable bleeding phenotype in an Amish pedigree with von Willebrand disease.

Authors:  Sweta Gupta; Meadow Heiman; Natalie Duncan; Jesse Hinckley; Jorge Di Paola; Amy D Shapiro
Journal:  Am J Hematol       Date:  2016-08-22       Impact factor: 10.047

2.  Improving diagnosis of von Willebrand disease: Reference ranges for von Willebrand factor multimer distribution.

Authors:  Inge Vangenechten; Alain Gadisseur
Journal:  Res Pract Thromb Haemost       Date:  2020-07-16

3.  Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers.

Authors:  Annette E Bowyer; Karen J Goodfellow; Holger Seidel; Philipp Westhofen; Francesca Stufano; Anne Goodeve; Stephen Kitchen; Michael Makris
Journal:  Res Pract Thromb Haemost       Date:  2018-08-12

4.  Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease.

Authors:  Johan Boender; Ferdows Atiq; Marjon H Cnossen; Johanna G van der Bom; Karin Fijnvandraat; Joke de Meris; Moniek P M de Maat; Karin P M van Galen; Britta A P Laros-van Gorkom; Karina Meijer; Jeroen Eikenboom; Frank W G Leebeek
Journal:  Hemasphere       Date:  2021-02-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.